<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01400646</url>
  </required_header>
  <id_info>
    <org_study_id>CR018664</org_study_id>
    <secondary_id>RIVAROXAFL1004</secondary_id>
    <secondary_id>2011-002890-46</secondary_id>
    <nct_id>NCT01400646</nct_id>
    <nct_alias>NCT01510925</nct_alias>
  </id_info>
  <brief_title>A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers</brief_title>
  <official_title>An Open-Label, Non-Randomized, Sequential Two-Treatment Period Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the pharmacodynamic (what the drug does to the body)&#xD;
      changes when transitioning from rivaroxaban 20 mg once daily to warfarin dosed to a&#xD;
      therapeutic level as measured by the International Normalized Ratio (INR) range of 2.0 to 3.0&#xD;
      in healthy volunteers. In addition, the pharmacokinetics (what the body does to the drug),&#xD;
      safety and tolerability of rivaroxaban during the transition to warfarin will be&#xD;
      investigated. The INR is obtained from a blood test, and is a measure for the clotting&#xD;
      tendency of the blood used for safe and adequate dosing of warfarin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label (study staff and healthy volunteers will know the&#xD;
      identity of treatment assigned), sequential 2-treatment period study in healthy adult&#xD;
      volunteers to explore the pharmacodynamic changes (changes drugs have on the body),&#xD;
      specifically in regard to blood coagulation (blood clotting) when healthy volunteers take&#xD;
      oral (by mouth) rivaroxaban followed by warfarin. Treatment Period 1: Rivaroxaban 20 mg/day&#xD;
      for 5 days then Rivaoxaban 20 mg/day + Warfarin 10 mg/day for 2-4 days then warfarin 0-15&#xD;
      mg/day for 4 days. Treatment Period 2: Warfarin 10 mg/day for 2-4 days, then 0-15 mg/day for&#xD;
      4 days. Treatment periods 1 and 2 will be separated by a washout period of at least 14 days.&#xD;
      In Treatment Periods 1 and 2, the dose of warfarin may be adjusted as specified by the&#xD;
      protocol and the last dose of warfarin in each Treatment period will be followed by a single&#xD;
      dose of Vitamin K. The approximate total study length for healthy adult volunteers enrolled&#xD;
      is approximately 72 days (includes a 28-day Screening Period, a 30-day Open-label Treatment&#xD;
      Phase, which includes the 7 days for a follow-up visit, and at least a 14-day washout between&#xD;
      treatment periods).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prothrombin time (PT)</measure>
    <time_frame>From Day 1 up to Day 9</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>International Ratio (INR)</measure>
    <time_frame>From Day 1 up to Day 9</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of Rivaroxaban</measure>
    <time_frame>Up to Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of Warfarin</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban + Warfarin Concomitant Therapy Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rivaroxaban monotherapy 20 mg/day for 5 days followed by Rivaroxaban 20 mg/day + Warfarin. 10 mg/day for &gt;= 2 to &lt;= 4 days concomitant therapy, then Warfarin monotherapy 0-15 mg/day for 4 days (Treatment Period 1). A 14-day washout period will separate Treatment Periods 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin Monotherapy Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Warfarin monotherapy 10 mg/day for &gt;=2 to &lt;=4 days, then Warfarin 0-15 mg/day for 4 days (Treatment Period 2). A 14-day washout period will separate Treatment Periods 1 and 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).</description>
    <arm_group_label>Rivaroxaban + Warfarin Concomitant Therapy Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).</description>
    <arm_group_label>Rivaroxaban + Warfarin Concomitant Therapy Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K</intervention_name>
    <description>Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).</description>
    <arm_group_label>Rivaroxaban + Warfarin Concomitant Therapy Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin K</intervention_name>
    <description>Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).</description>
    <arm_group_label>Warfarin Monotherapy Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)</description>
    <arm_group_label>Warfarin Monotherapy Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).</description>
    <arm_group_label>Rivaroxaban + Warfarin Concomitant Therapy Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).</description>
    <arm_group_label>Warfarin Monotherapy Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Volunteers must agree to provide a blood sample for pharmacogenomic testing and must&#xD;
             have less than 3 of the variant CYP2C9 and VKORC1 gene alleles associated with&#xD;
             increased warfarin sensitivity if their genetic status regarding these alleles is not&#xD;
             previously known&#xD;
&#xD;
          -  Have coagulation test results (INR, PT, and activated partial thromboplastin time&#xD;
             (aPTT) within clinically acceptable limits, blood pressure (after the volunteer is&#xD;
             supine for 5 minutes) between 90 and 140 mmHg systolic, inclusive, and between 50 and&#xD;
             90 mmHg diastolic&#xD;
&#xD;
          -  Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive), and body weight of&#xD;
             not less than 50 kg&#xD;
&#xD;
          -  Be a Non-smoker (Volunteers may not use nicotine-containing products within 3 months&#xD;
             prior to study drug administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history or current clinically significant medical illness, including (but not&#xD;
             limited to) of intracranial tumor or aneurysm&#xD;
&#xD;
          -  Have history of gastrointestinal disease (e.g., Crohn's disease) which could result in&#xD;
             impaired absorption of the study drugs or history of clinically significant&#xD;
             hemoptysis, excessive bruising, bleeding from nose or gums or known disorders with&#xD;
             increased bleeding risk (e.g., acute gastritis, acute peptic ulcer) or history of any&#xD;
             bleeding diathesis. Concomitant use (also within the last 2 weeks before start of the&#xD;
             study) of drugs that influenced the coagulation system, e.g., antiplatelet drugs&#xD;
             (e.g., acetylsalicylic acid, ticlopidine and clopidogrel&#xD;
&#xD;
          -  abciximab, tirofiban and integrelin) or other anticoagulants (antithrombins,&#xD;
             unfractionated heparins, low molecular weight heparins and hirudin, coumadin-type&#xD;
             anticoagulants phenprocoumon, warfarin, dabigatran, probenecide)&#xD;
&#xD;
          -  Use of medications known to affect the metabolic pathways (CYP3A4, or P-gp) within 14&#xD;
             days of study admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>July 21, 2011</study_first_submitted>
  <study_first_submitted_qc>July 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2011</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rivaroxaban</keyword>
  <keyword>JNJ-39039039</keyword>
  <keyword>BAY59-7939</keyword>
  <keyword>Warfarin</keyword>
  <keyword>Transition</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

